Greg Adams

Company: Elucida Oncology, Inc

Job title: Chief Scientific Officer

Seminars:

Development & Clinical Translation of ELU001, a Targeted Ultra- Small Topoisomerase 1 C’Dot Conjugate for the Treatment of Solid Tumors 10:30 am

ELU001 is an ultra-small, 6 nM exatecan conjugated C’Dot Drug Conjugate (CDC) that is targeted to Folate Receptor Alpha via folic acid moieties on its surface Understanding how Folate Receptor Alpha is an ideal target for CDC therapy due to its over expression on a variety of tumors and its limited expression on healthy tissues…Read more

day: Day Two